Smartphone app aims to combat malnutrition in head and neck cancer patients
NCT ID NCT06367257
First seen Jul 31, 2026 · Last updated Jul 31, 2026
Summary
This trial tests whether a smartphone app can help patients with head and neck cancer maintain their nutritional status during and after radiation therapy. Participants will use the app to regularly report their diet and well-being, with the goal of reducing weight loss and malnutrition. The study compares this app-based approach to standard supportive care.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- App-based nutritional monitoring and optimization
- What this could lead to
- If effective, this approach could help head and neck cancer patients maintain better nutrition and reduce weight loss during and after treatment, potentially improving their overall health and recovery.
- What could go wrong
- The trial is relatively small and focuses on a specific patient group. The app's effectiveness may vary based on patient adherence and technological comfort, and it may not significantly improve outcomes compared to standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 148 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2024
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients with squamous cell carcinoma in the head and neck region, who receive a postsurgical or definitive radio(chemo)therapy * Patients who have a smartphone on which the Emento app can be installed * Minimum age 18 years Exclusion Criteria: * Patients who are represented by a legal guardian * Patients who are not suitable for participation in the study due to a language barrier
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Squamous cell carcinoma of head and neck are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Universitätsklinikum Erlangen, Strahlenklinik
RECRUITINGErlangen, Bavaria, 91054, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Shorter radiation course tested for advanced head and neck cancer
- Can an experimental drug shrink advanced solid tumors?
- Can adding radiation boost immunotherapy against spread head and neck cancer?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- New hope for hard-to-treat cancers? experimental combo enters phase 2 trial
- New antibody drug aims to unleash immune system on Hard-to-Treat cancers